Signal from the log
Sling Therapeutics
123 M$ · Series C · United States · Biotech
Sling Therapeutics développe le linsitinib, une pilule qui bloque le récepteur IGF-1R dans l'orbitopathie thyroïdienne, une maladie auto-immune qui fait saillir les yeux hors de leur orbite. Le seul traitement approuvé, le Tepezza d'Amgen, demande huit perfusions. L'essai de phase 3 ORBIT a démarré.
Article
Announced on , logged by the watch of 16 September 2026.
- Operation
- Funding round
- Announced amount
- 123 M$
- Stage
- Series C
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Sujet traité. L'article donne les sources et la position de Bolus.
The investors
Led by Forbion , with TPG Life Sciences Innovations , Sectoral Asset Management
Provenance
Logged on 16 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Article The operation led to an article, with its sources checked one by one.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.